ORIGINAL ARTICLE

Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer

Karim Fizazi, M.D., Ph.D., NamPhuong Tran, M.D., Luis Fein, M.D.,
Nobuaki Matsubara, M.D., Alfredo Rodriguez-Antolin, M.D., Ph.D.,
Boris Y. Alekseev, M.D., Mustafa Özgüroğlu, M.D., Dingwei Ye, M.D.,
Susan Feyerabend, M.D., Andrew Protheroe, M.D., Ph.D., Peter De Porre, M.D.,
Thian Kheoh, Ph.D., Youn C. Park, Ph.D., Mary B. Todd, D.O.,
and Kim N. Chi, M.D., for the LATITUDE Investigators*

ABSTRACT

BACKGROUND

Abiraterone acetate, a drug that blocks endogenous androgen synthesis, plus prednisone is indicated for metastatic castration-resistant prostate cancer. We evaluated the clinical benefit of abiraterone acetate plus prednisone with androgen-deprivation therapy in patients with newly diagnosed, metastatic, castration-sensitive prostate cancer.

METHODS

In this double-blind, placebo-controlled, phase 3 trial, we randomly assigned 1199 patients to receive either androgen-deprivation therapy plus abiraterone acetate (1000 mg daily, given once daily as four 250-mg tablets) plus prednisone (5 mg daily) (the abiraterone group) or androgen-deprivation therapy plus dual placebos (the placebo group). The two primary end points were overall survival and radiographic progression-free survival.

RESULTS

After a median follow-up of 30.4 months at a planned interim analysis (after 406 patients had died), the median overall survival was significantly longer in the abiraterone group than in the placebo group (not reached vs. 34.7 months) (hazard ratio for death, 0.62; 95% confidence interval [CI], 0.51 to 0.76; P<0.001). The median length of radiographic progression-free survival was 33.0 months in the abiraterone group and 14.8 months in the placebo group (hazard ratio for disease progression or death, 0.47; 95% CI, 0.39 to 0.55; P<0.001). Significantly better outcomes in all secondary end points were observed in the abiraterone group, including the time until pain progression, next subsequent therapy for prostate cancer, initiation of chemotherapy, and prostate-specific antigen progression (P<0.001 for all comparisons), along with next symptomatic skeletal events (P=0.009). These findings led to the unanimous recommendation by the independent data and safety monitoring committee that the trial be unblinded and crossover be allowed for patients in the placebo group to receive abiraterone. Rates of grade 3 hypertension and hypokalemia were higher in the abiraterone group.

CONCLUSIONS

The addition of abiraterone acetate and prednisone to androgen-deprivation therapy significantly increased overall survival and radiographic progression-free survival in men with newly diagnosed, metastatic, castration-sensitive prostate cancer. (Funded by Janssen Research and Development; LATITUDE ClinicalTrials.gov number, NCT01715285.)

From Gustave Roussy, University of Paris Sud, Villejuif, France (K.F.); Janssen Research and Development, Los Angeles (N.T.), Beerse, Belgium (P.D.P.), San Diego, CA (T.K.), and Raritan, NJ (Y.C.P.); Instituto de Oncologia de Rosário, Rosário, Argentina (L.F.); National Cancer Center Hospital East, Chiba, Japan (N.M.); 12 de Octubre University Hospital, Madrid (A.R.-A.); P.A. Hertsen Moscow Cancer Research Institute, Moscow (B.Y.A.); Cerrahpaşa Medical Faculty, Istanbul University, Istanbul, Turkey (M.Ö.); Fudan University Shanghai Cancer Center, Shanghai, China (D.Y.); Studienpraxis Urologie, Nürtingen, Germany (S.F.); Oxford University Hospitals Foundation NHS Trust, Oxford, United Kingdom (A.P.); Janssen Global Services, Raritan, NJ (M.B.T.); and BC Cancer Agency, Vancouver, Canada (K.N.C.). Address reprint requests to Dr. Fizazi at the Department of Cancer Medicine, Gustave Roussy, University of Paris Sud, 114 Rue Edouard Vaillant, Villejuif 94800, France, or at karim.fizazi@ gustaveroussy.fr.

*A complete list of the LATITUDE investigators is provided in the Supplementary Appendix, available at NEJM.org.

METASTATIC, CASTRATION-SENSITIVE prostate cancer accounts for approximately 3% of all new prostate-cancer diagnoses in the United States.[1] Historically, androgen-deprivation therapy consisting of bilateral orchiectomy or luteinizing hormone–releasing hormone analogues, with or without first-generation androgen-receptor inhibitors, has been the standard of care.[2] Although the majority of patients have an initial response to androgen-deprivation therapy, most men with metastases have progression to castration-resistant prostate cancer within a median of approximately 1 year.[3-5] Resistance to androgen-deprivation therapy is largely driven by the reactivation of androgen-receptor signaling through persistent adrenal androgen production, up-regulation of intratumoral testosterone production, modification of the biologic characteristics of androgen receptors, and steroidogenic parallel pathways.[2]

The clinical benefit of adding docetaxel to androgen-deprivation therapy versus treatment with androgen-deprivation therapy alone has been shown in three randomized, phase 3 trials — Chemohormonal Therapy Versus Androgen Ablation Randomized Trial for Extensive Disease in Prostate Cancer (CHAARTED),[5,6] Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy (STAMPEDE),[7] and GETUG-15[3,8] — which collectively included more than 3000 men with metastatic, castration-sensitive prostate cancer. Androgen-deprivation therapy plus docetaxel is now a standard of care for men with metastatic, castration-sensitive prostate cancer who are eligible for chemotherapy, particularly those with a high metastatic burden, as defined in the respective studies.[9-11] Barriers to the use of docetaxel include advanced patient age, poor performance status, coexisting illnesses, and patient preferences.[9,12] Retrospective analyses exploring real-world practice patterns[13,14] indicate that men with newly diagnosed, metastatic, castration-sensitive prostate cancer who are not being treated in clinical trials may be nearly a decade older than those treated in clinical trials. The concern with respect to chemotherapy-related toxicity and the effect of coexisting illnesses on complications is based on the severity of the toxicity that has been observed. Chemotherapy-related deaths were documented in all three randomized trials in which docetaxel was added to androgen-deprivation therapy.[3,5,7]

Abiraterone acetate, the prodrug of abiraterone, inhibits cytochrome P-450c17, a critical enzyme in androgen biosynthesis.[15,16] Recent studies implicate its active D4A metabolite in antitumor effects, presumably through blockade of multiple steroidogenic enzymes and antagonism of the androgen receptor.[17] Abiraterone acetate (hereafter referred to as abiraterone) in combination with prednisone has been shown to significantly increase overall survival and provide additional clinical benefits in patients with metastatic, castration-resistant prostate cancer who have not received chemotherapy and in those who have received previous docetaxel.[18-22] The combination of abiraterone plus prednisone and androgen-deprivation therapy has been shown to reduce tumor burden in men with high-risk, localized prostate cancer who are receiving neoadjuvant therapy, which suggests a potential role for inhibiting extragonadal androgen biosynthesis before the emergence of castration resistance in men with newly diagnosed, metastatic, castration-sensitive prostate cancer.[23,24] In LATITUDE, a multinational, randomized, double-blind, placebo-controlled, phase 3 trial, we evaluated the addition of abiraterone plus prednisone to androgen-deprivation therapy, as compared with androgen-deprivation therapy and dual placebos, on overall survival, radiographic progression-free survival, and clinically relevant measures in men with newly diagnosed, metastatic, castration-sensitive prostate cancer.

METHODS

TRIAL DESIGN AND CONDUCT

The trial was conducted at 235 sites in 34 countries in Europe, the Asia–Pacific region, Latin America, and Canada. The trial protocol (available with the full text of this article at NEJM.org) was approved by the review board at each participating institution. The trial was conducted according to the principles of the Declaration of Helsinki and the International Conference on Harmonisation Good Clinical Practice Guidelines. All the patients provided written informed consent.

An independent data and safety monitoring committee was commissioned by the sponsor, Janssen Research and Development, to review safety data on a regular basis and review efficacy data at planned interim analyses. The trial

was designed by the senior academic authors and employees of the sponsor. Data were transcribed by trial personnel from source documents onto an electronic data-capture system prepared by the sponsor. The data analyses were performed by statisticians employed by the sponsor. All the authors assume responsibility for the completeness and integrity of the data and for the fidelity of the trial to the protocol. All the academic authors had full access to all parts of the data and drafted the manuscript with sponsor input, and all the coauthors subsequently provided input. The sponsor provided funding for editorial assistance. All the authors and participating institutions have agreements with the sponsor regarding data confidentiality.

PATIENTS AND TREATMENTS

Eligible patients were required to be at least 18 years of age and to have an Eastern Cooperative Oncology Group (ECOG) performance-status score of 0 to 2 (on a 5-point scale, with higher numbers indicating greater disability) with newly diagnosed (≤3 months before randomization), pathologically confirmed prostate cancer without neuroendocrine differentiation or small-cell histologic features. All the patients had high-risk, metastatic, castration-sensitive prostate cancer, as documented by a positive bone scan or metastatic lesions at the time of diagnosis on computed tomography (CT) or magnetic resonance imaging (MRI), according to Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1. In addition, the patients were required to have at least two of the three following high-risk factors associated with poor prognosis: a Gleason score of 8 or more (on a scale of 2 to 10, with higher scores indicating more aggressive disease), at least three bone lesions, and the presence of measurable visceral metastasis. Patients were excluded if they had received previous chemotherapy, radiation therapy, or surgery for metastatic prostate cancer, with the exception of 3 months or less of androgen-deprivation therapy with luteinizing hormone–releasing hormone analogues or orchiectomy with or without concurrent first-generation androgen-receptor antagonists before baseline or one course of palliative radiation or surgical therapy to treat symptoms associated with metastatic disease.

Patients were randomly assigned in a 1:1 ratio to receive androgen-deprivation therapy and abiraterone acetate (1000 mg daily, given once daily as four 250-mg tablets) and prednisone (5 mg daily) (the abiraterone group) or androgen-deprivation therapy and placebos (the placebo group). Patients were stratified according to the presence or absence of measurable visceral disease and ECOG performance-status score (0 or 1 vs. 2). Abiraterone or placebo was administered at least 1 hour before or 2 hours after a meal. All the patients who had not undergone surgical castration received ongoing androgen-deprivation therapy to reach or maintain a serum testosterone level of less than 50 ng per deciliter (1.7 nmol per liter). Safety and dosing adherence were evaluated during each trial visit, at treatment discontinuation (if applicable), and at the end-of-trial visit.

END POINTS

The two primary efficacy end points were overall survival and radiographic progression-free survival. Overall survival was defined as the time from randomization to death from any cause, and radiographic progression-free survival as the time from randomization to the occurrence of radiographic progression or death from any cause. Radiographic progression of soft-tissue lesions was evaluated by either CT or MRI on the basis of RECIST, version 1.1. Progression on bone scanning was assessed by adaptation of Prostate Cancer Working Group 2 criteria (Table S1 in the Supplementary Appendix, available at NEJM.org).[25] Potential bias favoring the abiraterone group in the assessment of radiographic progression by investigators was audited with the use of the method of the Pharmaceutical Research and Manufacturers Association[26] in a sample of 202 randomly selected patients with blinded central review.

Prespecified secondary end points were the time to the next "skeletal-related event" (described here as a "symptomatic skeletal event," which was defined as a clinical or pathological fracture, spinal-cord compression, palliative radiation to bone, or surgery involving bone), time to progression with respect to prostate-specific antigen (PSA) level on the basis of Prostate Cancer Working Group 2 criteria,[25] time to the next therapy for prostate cancer, time to initiation of chemotherapy, and time to pain progression. Pain progression was defined as an increase of at least 30% from baseline in the worst pain

category on the Brief Pain Inventory–Short Form as observed at two consecutive evaluations performed at least 4 weeks apart.

ASSESSMENTS

Efficacy assessments included sequential radiographic imaging to assess radiographic progression-free survival (CT or MRI and bone scanning) performed every 4 months, starting at week 16. PSA levels were measured at baseline,

monthly in the first year, and then every 2 months until end-of-trial treatment. Patients underwent serial monitoring of vital signs, serum hematologic and chemical findings, liver-function tests, and serum testosterone levels. Adverse events were graded with the use of the Common Terminology Criteria for Adverse Events of the National Cancer Institute, version 4.0.

STATISTICAL ANALYSIS

The overall level of significance was 0.05, with allocation between the two primary end points of overall survival (0.049) and radiographic progression-free survival (0.001) (Table S2 in the Supplementary Appendix). For overall survival, 852 events were required at the final analysis to detect a hazard ratio of 0.81 at a two-tailed significance level of 0.049, with a statistical power of 85%. An analysis of radiographic progression-free survival was planned when 565 progressions or deaths had been observed, which would provide a statistical power of 94% to detect a hazard ratio of 0.667 at a two-tailed significance level of 0.001. Two interim analyses were included (Table S2 in the Supplementary Appendix). The overall survival analyses incorporated the group sequential design with an alpha spending function that was calculated as Wang–Tsiatis power boundaries of shape parameter 0.2 (which shape the probability distribution). Secondary end points were tested with the use of the Hochberg test procedure to control the familywise type I error rate. The primary statistical method of comparison for time-to-event end points was the stratified log-rank test, according to the stratification factors. The Cox proportional-hazards model was used to estimate the hazard ratio and its associated 95% confidence interval.

RESULTS

PATIENTS AND TREATMENTS

A total of 1199 patients underwent randomization from February 12, 2013, through December 11, 2014. Of these patients, 597 were assigned to the abiraterone group and 602 to the placebo group (Fig. S1 in the Supplementary Appendix). The baseline demographic and disease characteristics were well balanced between the two groups (Table S3 in the Supplementary Appendix). The results presented here are based on the clinical cutoff date of October 31, 2016, for the

Figure 1. Kaplan–Meier Estimates of the Two Primary End Points.
Shown are data for overall survival (Panel A) and for radiographic progression-free survival (Panel B). The dashed lines indicate the median. The median rate of overall survival was not reached in the abiraterone group and was 34.7 months in the placebo group; the corresponding medians for progression-free survival were 33.0 months and 14.8 months. CI denotes confidence interval.

first interim analysis of overall survival, at which time 406 deaths and 593 radiographic progressions or deaths had occurred. At a median follow-up of 30.4 months, the median time that the patients received the intervention was 24 months in the abiraterone group and 14 months in the placebo group. As a result of the findings at the time of the interim analysis, the independent data and safety monitoring committee unanimously recommended on January 12, 2017, that the trial be unblinded to allow crossover among the patients in the placebo group to receive abiraterone.

END POINTS
Overall Survival
The first interim analysis was performed after 406 deaths (48% of the 852 deaths that were included in the final analysis) and a median follow-up of 30.4 months. Of these deaths, 169 of 597 (28%) occurred in the abiraterone group and 237 of 602 (39%) in the placebo group. The overall rate of survival at 3 years was 66% in the abiraterone group and 49% in the placebo group (Fig. 1A). The rate of death from any cause was 28% in the abiraterone group and 39% in the placebo group (Table S4 in the Supplementary Appendix). The relative risk of death was 38% lower in the abiraterone group than in the placebo group (hazard ratio, 0.62; 95% confidence interval [CI], 0.51 to 0.76; P<0.001). The treatment effect of abiraterone on overall survival was consis-

tently favorable across nearly all prespecified subgroups (Fig. S2 in the Supplementary Appendix).

Radiographic Progression-free Survival
At the time of the analysis, the median progression-free survival was 33.0 months in the abiraterone group and 14.8 months in the placebo group (239 events vs. 354 events) — a 53% lower relative risk of radiographic progression or death in the abiraterone group than in the placebo group (hazard ratio, 0.47; 95% CI, 0.39 to 0.55; P<0.001) (Fig. 1B). The treatment effect in the abiraterone group was consistent across nearly all prespecified subgroups (Fig. S3 in the Supplementary Appendix).

SECONDARY AND EXPLORATORY END POINTS
The superiority of abiraterone over placebo was shown for all secondary end points (Table 1 and Fig. 2, and Figs. S4 and S5 in the Supplementary Appendix). The numbers of patients who received one or multiple life-prolonging subsequent therapies were 125 (21%) in the abiraterone group and 246 (41%) in the placebo group (Table S5 in the Supplementary Appendix). Docetaxel was the most common post-progression treatment in the two groups.

SAFETY
Grade 3 or 4 adverse events were reported in 63% of the patients in the abiraterone group and

Table 1. Prespecified Secondary and Exploratory Efficacy End Points.*

| End Point	Abiraterone Group (N = 597)	Placebo Group (N = 602)	Hazard Ratio (95% CI)	P Value†
Secondary end points				
Median time to pain progression (mo)	NR	16.6	0.70 (0.58–0.83)	<0.001
Median time to PSA progression (mo)	33.2	7.4	0.30 (0.26–0.35)	<0.001
Median time to next symptomatic skeletal event (mo)	NR	NR	0.70 (0.54–0.92)	0.009
Median time to chemotherapy (mo)	NR	38.9	0.44 (0.35–0.56)	<0.001
Median time to subsequent prostate cancer therapy (mo)	NR	21.6	0.42 (0.35–0.50)	<0.001
Exploratory end point				
Patients with a PSA response (%)‡	91	67	1.36 (1.28–1.45)	<0.001

* CI denotes confidence interval, PSA prostate-specific antigen, and NR not reached.
† P values for secondary end points were calculated by means of a stratified log-rank test and those for the exploratory end point by means of a chi-square test.
‡ A PSA response was defined as a decrease of at least 50% from the baseline value. The comparison for this exploratory end point was calculated as an odds ratio.

A Pain Progression

No. at Risk

	0	6	12	18	24	30	36	42
Abiraterone	597	395	297	247	181	96	39	2
Placebo	602	332	211	137	82	36	7	0

B PSA Progression

No. at Risk

	0	4	8	12	16	20	24	28	32	36	40	44
Abiraterone	597	520	447	379	340	285	227	162	95	48	18	0
Placebo	602	393	250	172	129	102	65	33	19	8	5	0

C Symptomatic Skeletal Event

No. at Risk

	0	4	8	12	16	20	24	28	32	36	40	44
Abiraterone	597	562	531	501	465	423	355	261	159	83	29	0
Placebo	602	566	501	458	409	358	293	199	118	52	17	0

Figure 2. Kaplan–Meier Estimates of Secondary End Points.

Shown are the time to pain progression (Panel A), the time to prostate-specific antigen (PSA) progression (Panel B), and the time to the next symptomatic skeletal event (Panel C). The dashed lines indicate the median. All analyses were performed with the use of a stratified log-rank test according to the stratification factors. The time to pain progression was time from randomization to the first increase of at least 30% from baseline in the worst-pain category on the Brief Pain Inventory–Short Form observed at two consecutive evaluations at least 4 weeks apart. The median value for this category was not reached in the abiraterone group and was 16.6 months in the placebo group; the corresponding medians were 33.2 months and 7.4 months for PSA progression; the medians for symptomatic skeletal events were not reached in either group.

in 48% of those in the placebo group (Table 2). The numbers of patients with serious adverse events were similar in the two groups. The frequency of adverse events leading to treatment discontinuation was 12% in the abiraterone group and 10% in the placebo group (Table S6 in the Supplementary Appendix). Adverse events that led to a dose modification or interruption were reported in 32% of the patients in the abiraterone group and in 17% of those in the placebo group. Grade 3 mineralocorticoid-related toxic effects of special interest, including hypertension and hypokalemia, occurred at a higher frequency in the abiraterone group than in the placebo group; rates of grade 3 and grade 4 hypertension were 20% and 0%, respectively, in the abiraterone group and 10% and 0.2%, respectively, in the placebo group, with corresponding rates of hypokalemia of 10% and 0.8% in the abiraterone group and of 1% and 0.2% in the placebo group (Table 2).

DISCUSSION

In this phase 3 trial involving men with high-risk, newly diagnosed, metastatic, castration-sensitive prostate cancer, the rate of overall survival was significantly higher among those who received androgen-deprivation therapy plus abiraterone and prednisone than among those who received androgen-deprivation therapy plus placebos, with a 38% lower relative risk of death

Table 2. Adverse Events.*

Adverse Event	Abiraterone Group (N = 597)			Placebo Group (N = 602)		
	number of patients (percent)					
Any adverse event	558 (93)			557 (93)		
Grade 3 or 4 adverse event	374 (63)			287 (48)		
Any serious adverse event	165 (28)			146 (24)		
Any adverse event leading to treatment discontinuation	73 (12)			61 (10)		
Adverse event leading to death	28 (5)			24 (4)		
	All Grades	Grade 3	Grade 4	All Grades	Grade 3	Grade 4
Graded adverse events†						
Hypertension	219 (37)	121 (20)	0	133 (22)	59 (10)	1 (<1)
Hypokalemia	122 (20)	57 (10)	5 (1)	22 (4)	7 (1)	1 (<1)
ALT increased	98 (16)	31 (5)	2 (<1)	77 (13)	8 (1)	0
Hyperglycemia	75 (13)	26 (4)	1 (<1)	68 (11)	18 (3)	0
AST increased	87 (15)	25 (4)	1 (<1)	68 (11)	9 (1)	0
Bone pain	74 (12)	20 (3)	0	88 (15)	17 (3)	0
Cardiac disorder						
Any	74 (12)	15 (3)	5 (1)	47 (8)	6 (1)	0
Atrial fibrillation	8 (1)	2 (<1)	0	2 (<1)	1 (<1)	0
Anemia	54 (9)	12 (2)	3 (1)	85 (14)	26 (4)	1 (<1)
Back pain	110 (18)	14 (2)	0	123 (20)	19 (3)	0
Fatigue	77 (13)	10 (2)	0	86 (14)	14 (2)	0
Spinal-cord compression	14 (2)	12 (2)	0	12 (2)	7 (1)	3 (<1)

* Listed are the most common adverse events and events of special interest. The latter were selected on the basis of the safety profile of phase 2 and phase 3 studies of abiraterone. ALT denotes alanine aminotransferase, and AST aspartate aminotransferase.

† Listed in descending order are events that were reported in at least 2% of the patients in either group. Among other events of special interest, grade 3 peripheral edema was reported in 0.3% of the patients in the abiraterone group and in 0.5% of those in the placebo group; grade 3 or 4 fluid retention or congestive heart failure was not reported in either group. Grade 3 hot flush was reported in one patient in the placebo group, and grade 1 irritability was reported in three patients in the abiraterone group.

(hazard ratio, 0.62) in the abiraterone group. The addition of abiraterone plus prednisone to androgen-deprivation therapy also significantly prolonged radiographic progression-free survival (hazard ratio, 0.47) and all secondary end points. Since the between-group difference for overall survival was significant at the time of the first interim analysis and unblinding of the trial, this analysis is considered to be final.

We explored the utility of more effective blockade of the androgen-receptor axis with the addition of abiraterone to androgen-deprivation therapy in men with metastatic, castration-sensitive prostate cancer. Our data support the hypothesis that more effective inhibition of androgen-receptor signaling as a component of the initial systemic therapy in patients with castration-sensitive prostate cancer leads to improved outcomes. The clinical benefit that we observed contrasts with that from the many previous attempts with castration and first-generation androgen-receptor inhibitors,[27,28] which showed only a small improvement with a combined androgen-blockade approach,[29] presumably owing to the lower potency and partial agonist activity of these drugs. Several other ongoing randomized, phase 3 trials in this patient population are examining androgen receptor–signaling combina-

tion therapies with androgen-deprivation therapy (Table S7 in the Supplementary Appendix) and are exploring whether these treatments can be added to androgen-deprivation therapy plus docetaxel in patients with metastatic, castration-sensitive prostate cancer. The assessment of efficacy of subsequent therapies, including the types of disease progression in patients who were receiving treatment, will require more long-term analysis.

Men with newly diagnosed, metastatic, castration-sensitive prostate cancer can have variable outcomes, so we purposely enrolled those who were considered to have at least two high-risk prognostic features (e.g., a Gleason score of ≥8, the presence of ≥3 bone lesions, or the presence of measurable visceral metastasis),[30-33] all of which are associated with poor survival. In addition, 50% of the patients had symptomatic disease at baseline. The patient population appears to be similar to high-burden disease populations in the three randomized trials that evaluated androgen-deprivation therapy plus docetaxel,[3,5,7] since the outcomes in the control groups were similar across those studies. After a median follow-up of 7 years in GETUG-15, a nonsignificant 22% reduction in the relative risk of death was observed in patients with high-volume disease.[8] A significant 27% reduction in the relative risk of death (and a reduction of 37% in patients with high-volume disease) with androgen-deprivation therapy plus docetaxel was observed after a 53.7-month follow-up (approximately 50% of deaths) in CHAARTED.[6] In STAMPEDE, a significant 24% risk reduction in death was observed among patients with metastatic, castration-sensitive prostate cancer.[7] (The STAMPEDE investigators now report in the *Journal* the results of another trial of abiraterone plus prednisone in men with locally advanced or metastatic prostate cancer.[34]) In our trial, the efficacy of abiraterone, with a 38% reduction in the risk of death among patients who had not received previous treatment for metastatic disease, compares favorably with previous findings. Of note, the early use of abiraterone plus prednisone resulted in increased survival, even though more patients in the placebo group received life-prolonging treatments after progression.

The overall safety profile in the abiraterone group was consistent with those in previous studies involving patients with metastatic, castration-resistant prostate cancer, with an anticipated elevated incidence of mineralocorticoid-related hypertension and hypokalemia. The incidence of grade 3 hypertension in the abiraterone group as compared with the placebo group (20% vs. 10%) was greater than that observed in previous studies of abiraterone involving patients with metastatic, castration-resistant prostate cancer. However, this difference may be attributable to our use of stricter grading with version 4.0 of the Common Terminology Criteria for Adverse Events. The increased rate of hypertension in the abiraterone group did not appear to have any serious sequelae; 2 patients in each group died of stroke, and 10 patients in the abiraterone group and 6 in the placebo group died of cardiac disorders. The incidence of hypokalemia was also higher than that reported in previous phase 3 studies of abiraterone involving patients with metastatic, castration-resistant prostate cancer, but only 2 patients discontinued treatment because of hypokalemia and there were no hypokalemia-related deaths. The apparent increase in mineralocorticoid-associated adverse events may reflect the fact that the prednisone dose used in our trial was lower than that used in previous studies of abiraterone (5 mg vs. 10 mg) but may also be related to the longer duration of abiraterone treatment in our trial than in previous trials (24 months in the LATITUDE trial vs. 13.8 months in COU-AA-302[22]). The observed degrees of hypertension and hypokalemia were both medically manageable, only rarely required treatment discontinuation, and seldom led to serious consequences, all factors that point to the need for proper and timely management.

In conclusion, among men with newly diagnosed, metastatic, castration-sensitive prostate cancer, the addition of abiraterone plus prednisone to androgen-deprivation therapy was associated with longer overall survival and longer radiographic progression-free survival than was androgen-deprivation therapy alone. Rates of grade 3 hypertension and hypokalemia were higher in the abiraterone group.

REFERENCES

1. Weiner AB, Matulewicz RS, Eggener SE, Schaeffer EM. Increasing incidence of metastatic prostate cancer in the United States (2004-2013). Prostate Cancer Prostatic Dis 2016;19:395-7.

2. Yamaoka M, Hara T, Kusaka M. Overcoming persistent dependency on androgen signaling after progression to castration-resistant prostate cancer. Clin Cancer Res 2010;16:4319-24.

3. Gravis G, Fizazi K, Joly F, et al. Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial. Lancet Oncol 2013;14:149-58.

4. James ND, Spears MR, Clarke NW, et al. Survival with newly diagnosed metastatic prostate cancer in the "docetaxel era": data from 917 patients in the control arm of the STAMPEDE trial (MRC PR08, CRUK/06/019). Eur Urol 2015;67:1028-38.

5. Sweeney CJ, Chen Y-H, Carducci M, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med 2015;373:737-46.

6. Sweeney C, Chen Y-H, Liu G, et al. Long term efficacy and QOL data of chemohormonal therapy in low and high volume hormone naive metastatic prostate cancer: E3805 CHAARTED trial. Ann Oncol 2016; 27:243-65.

7. James ND, Sydes MR, Clarke NW, et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multi-arm, multistage, platform randomised controlled trial. Lancet 2016;387:1163-77.

8. Gravis G, Boher JM, Joly F, et al. Androgen deprivation therapy (ADT) plus docetaxel versus ADT alone in metastatic non castrate prostate cancer: impact of metastatic burden and long-term survival analysis of the randomized phase 3 GETUG-AFU15 trial. Eur Urol 2016;70: 256-62.

9. Cornford P, Bellmunt J, Bolla M, et al. EAU-ESTRO-SIOG guidelines on prostate cancer. II. Treatment of relapsing, metastatic, and castration-resistant prostate cancer. Eur Urol 2017;71:630-42.

10. Gillessen S, Omlin A, Attard G, et al. Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. Ann Oncol 2015;26:1589-604.

11. Parker C, Gillessen S, Heidenreich A, Horwich A. Cancer of the prostate: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2015; 26:Suppl 5:v69-v77.

12. Fizazi K, Jenkins C, Tannock IF. Should docetaxel be standard of care for patients with metastatic hormone-sensitive prostate cancer? Pro and contra. Ann Oncol 2015;26:1660-7.

13. Hussain M, Tangen CM, Berry DL, et al. Intermittent versus continuous androgen deprivation in prostate cancer. N Engl J Med 2013;368:1314-25.

14. Scosyrev E, Messing EM, Mohile S, Golijanin D, Wu G. Prostate cancer in the elderly: frequency of advanced disease at presentation and disease-specific mortality. Cancer 2012;118:3062-70.

15. Barrie SE, Potter GA, Goddard PM, Haynes BP, Dowsett M, Jarman M. Pharmacology of novel steroidal inhibitors of cytochrome P450(17) alpha (17 alpha-hydroxylase/C17-20 lyase). J Steroid Biochem Mol Biol 1994;50:267-73.

16. O'Donnell A, Judson I, Dowsett M, et al. Hormonal impact of the 17alpha-hydroxylase/C(17,20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer. Br J Cancer 2004;90:2317-25.

17. Li Z, Bishop AC, Alyamani M, et al. Conversion of abiraterone to D4A drives anti-tumour activity in prostate cancer. Nature 2015;523:347-51.

18. de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011;364:1995-2005.

19. Fizazi K, Scher HI, Molina A, et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 2012;13:983-92.

20. Ryan CJ, Smith MR, de Bono JS, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 2013;368:138-48.

21. Rathkopf DE, Smith MR, de Bono JS, et al. Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302). Eur Urol 2014;66: 815-25.

22. Ryan CJ, Smith MR, Fizazi K, et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 2015;16:152-60.

23. Taplin ME, Montgomery B, Logothetis CJ, et al. Intense androgen-deprivation therapy with abiraterone acetate plus leuprolide acetate in patients with localized high-risk prostate cancer: results of a randomized phase II neoadjuvant study. J Clin Oncol 2014;32:3705-15.

24. Efstathiou E, Li W, Gormley M, et al. Biological heterogeneity in localized high-risk prostate cancer (LHRPC) from a study of neoadjuvant abiraterone acetate plus leuprolide acetate (LHRHa) versus LHRHa. J Clin Oncol 2015;33:Suppl:5005. abstract.

25. Scher HI, Halabi S, Tannock I, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 2008;26:1148-59.

26. Amit O, Mannino F, Stone AM, et al. Blinded independent central review of progression in cancer clinical trials: results from a meta-analysis. Eur J Cancer 2011; 47:1772-8.

27. Reese DM. Choice of hormonal therapy for prostate cancer. Lancet 2000;355: 1474-5.

28. Eisenberger MA, Blumenstein BA, Crawford ED, et al. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med 1998;339: 1036-42.

29. Prostate Cancer Trialists' Collaborative Group. Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Lancet 2000;355: 1491-8.

30. Glass TR, Tangen CM, Crawford ED, Thompson I. Metastatic carcinoma of the prostate: identifying prognostic groups using recursive partitioning. J Urol 2003; 169:164-9.

31. Tangen CM, Faulkner JR, Crawford ED, et al. Ten-year survival in patients with metastatic prostate cancer. Clin Prostate Cancer 2003;2:41-5.

32. Millikan RE, Wen S, Pagliaro LC, et al. Phase III trial of androgen ablation with or without three cycles of systemic chemotherapy for advanced prostate cancer. J Clin Oncol 2008;26:5936-42.

33. Gravis G, Boher JM, Fizazi K, et al. Prognostic factors for survival in noncastrate metastatic prostate cancer: validation of the Glass model and development of a novel simplified prognostic model. Eur Urol 2015;68:196-204.

34. James ND, de Bono JS, Spears MR, et al. Abiraterone for prostate cancer not previously treated with hormone therapy. N Engl J Med. DOI: 10.1056/NEJM oa1702900.

Copyright © 2017 Massachusetts Medical Society.